Fed’s Powell opens door to potential rate cuts at Jackson Hole
Enliven Therapeutics, Inc. (NASDAQ:ELVN), a biotechnology company with a market capitalization of approximately $968 million, recently reported that its Chief Financial Officer, Benjamin Hohl, executed a series of stock transactions. On March 27, 2025, Hohl sold 3,250 shares of the company’s common stock, generating proceeds of $69,320. The sales were conducted at prices ranging from $20.75 to $21.645, with a weighted average sale price of $21.3295. According to InvestingPro data, the stock has declined over 12% in the past week, currently trading at $19.68.
In a related move, Hohl exercised stock options to acquire the same number of shares—3,250—at a price of $2.48 per share. This transaction, part of a pre-established Rule 10b5-1 trading plan, resulted in a total acquisition cost of $8,060. Following these transactions, Hohl holds 23,000 shares of Enliven Therapeutics directly. InvestingPro analysis shows the company maintains robust liquidity with a current ratio of 20x, while analyst price targets range from $33 to $42.
These transactions reflect Hohl’s strategic financial maneuvers as part of his ongoing management of personal and professional assets within the company. For deeper insights into Enliven’s financial health and additional analysis, investors can access 7 more exclusive tips on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.